ArticleJournal of inflammation research2026
Predictive Value of NLRP3 Inflammasome Activation for Unstable Plaques and Major Adverse Cardiovascular Events in Coronary Heart Disease.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of Nod-like receptor protein 3 (NLRP3) inflammasome activation in unstable plaques remains incompletely elucidated. This study aimed to investigate whether the NLRP3 inflammasome and its downstream cytokine IL-1 Methods: The study enrolled 232 patients diagnosed with CHD at Gansu Provincial Hospital between May 2023 and June 2024. Based on standardized plaque vulnerability criteria assessed by intravascular ultrasound (IVUS) or optical coherence tomography (OCT), patients were divided into a stable plaque group (n=143) and an unstable plaque group (n=89). Serum concentrations of NLRP3 and IL-1 Results: NLRP3 and IL-1 Conclusion: NLRP3 inflammasome activation is a key predictor of unstable plaques (including rupture and erosion) and subsequent MACE in CHD patients, highlighting its strong promise as a clinical biomarker for refining risk stratification and guiding future therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.